Superworth4D Molecular Therapeutics price to sales ratio FDMT
Market value divided by revenue over the last twelve months, since 2023.
- Today, Oct 23, 2026
- 6.5×
- 4-year median
- 23.8×
- Against its 4-year history
- 25th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 5.1× to 193×
- Peer median
- 3.6×
4D Molecular Therapeutics' price to sales ratio is 6.5× as of Oct 23, 2026.
That is below its 4-year median of 23.8×, lower than on 75% of days in the last 4 years.
Over that time it ranged from 5.1× in May 2026 to 193× in Oct 2023.
The median for 4 biotech stocks of a similar size is 3.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 6.5× | 5.1× | 9.5× |
| 2025 | n/m a value too high to mean anything | ||
| 2024 | 59.7× | 33.1× | 76.1× |
| 2023 | 39.4× | 21.5× | 193× |
Against its peers
Companies in Biotechnology nearest 4D Molecular Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| FDMT4D Molecular Therapeutics | 6.5× |
| MGTXMeiraGTx | 2.2× |
| PLXProtalix BioTherapeutics | 2.5× |
| VCELVericel | 7.1× |
| ADMAAdma Biologics | 4.7× |
| Peer median | 3.6× |
Where 4D Molecular Therapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on 4D Molecular Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.